Skip to main content
Brian Kobilka, MD, Internal Medicine, Stanford, CA

BrianKobilkaMD

Internal Medicine Stanford, CA

Cardiology

Professor, Molecular & Cellular Physiology, Stanford University Medical Center

Dr. Kobilka is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kobilka's full profile

Already have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Cardiovascular Disease, 1984 - 1987
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1981 - 1984
  • Yale School of Medicine
    Yale School of MedicineClass of 1981

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1990 - 2026
  • NC State Medical License
    NC State Medical License 1984 - 1999
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 1995
  • Investigator Alumnus Howard Hughes Medical Institute, 1987

Publications & Presentations

PubMed

Journal Articles

  • Crystal Structure of the Natural Anion-Conducting Channelrhodopsin GtACR1  
    Lief E Fenno, Karl Deisseroth, Brian K Kobilka, Nature
  • Structural Mechanisms of Selectivity and Gating in Anion Channelrhodopsins  
    Karl Deisseroth, Lief E Fenno, Brian K Kobilka, Nature
  • Structure of the Μ-opioid Receptor–Gi Protein Complex  
    Brian Kobilka, MD, Nature

Press Mentions

  • WashU, Pharmacy Scientists Alter Fentanyl, Aim to Make It Less Lethal, Less Addictive
    WashU, Pharmacy Scientists Alter Fentanyl, Aim to Make It Less Lethal, Less AddictiveNovember 30th, 2022
  • The Many Ways Stanford Medicine Is Responding to the Opioid Crisis
    The Many Ways Stanford Medicine Is Responding to the Opioid CrisisMay 6th, 2022
  • Recursion Founders Gin Fortunes as IPO Backers Shower $436M on One of the Biggest Boasts in AI -- Based on Some Very Small Deals
    Recursion Founders Gin Fortunes as IPO Backers Shower $436M on One of the Biggest Boasts in AI -- Based on Some Very Small DealsApril 17th, 2021
  • Join now to see all